Centre Hospitalier Universitaire (CHU) de Nice

Nice 06000

0 studies enrolling now · 1 studies all time

What they study most

Acute Myeloid Leukemia (AML), Secondary to Myeloproliferative Neoplasms (MPN), Relapsed or Refractory Acute Myeloid Leukemia (AML)

Studies at this site

• An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 When Administered Alone and in Combination With Low-Dose Cytarabine (LDAC) or Decitabine in Patients With Acute Myeloid Leukemia (AML) — Stopped early